The global blood plasma derivatives market is expected to grow at a CAGR of around 9.5% from 2020 to 2027 and expected to reach the market value of around US$ 50.3 Bn by 2027.
The Food and Drug Administration regulates blood collection, preparation, and testing (FDA). Whole blood is collected from volunteer donors and separated into components such as red blood cells, platelets, plasma, and cryoprecipitate. Granulocytes and other white blood cells, while occasionally transfused, are not FDA-approved products (but they generally are collected using aphaeresis in FDA-registered facilities). Platelets, red blood cells, and plasma can also be collected using apheresis, which involves passing the blood through a machine that separates blood components and returns uncollected components to the donor. Plasma can be prepared from whole blood or collected by aphaeresis for transfusion or further processing into plasma protein derivatives such as albumin (human), clotting factor concentrates, and Immune Globulin Intravenous (IGIV). Plasma proteins are derived from plasma collected specifically for the purpose of manufacturing these derivatives or from whole blood plasma. Plasma protein derivatives are created by pooling plasma from multiple donors and separating the desired proteins, such as immune globulins and clotting factors, through a fractionation process.
COVID-19 impact on blood plasma derivatives market
Convalescent plasma therapy, according to a report released by the Mayo Foundation for Medical Education and Research (MFMER), uses blood from people who have recovered from illness to help others recover. The Food and Drug Administration (FDA) of the United States has granted emergency approval for convalescent plasma therapy with high antibody levels to treat COVID-19. It may be used for some hospitalized COVID-19 patients who are either in the early stages of their illness or have weakened immune systems. Blood donated by COVID-19 survivors contains antibodies to the virus that causes it. Blood cells are removed from donated blood, leaving behind liquid (plasma) and antibodies. These can be given to people who have COVID-19 to help them fight the virus. People with COVID-19 who are in the hospital and are early in their illness or have a weakened immune system may be given convalescent plasma therapy. Convalescent plasma therapy may aid in the recovery of COVID-19 patients. It may lessen the severity of the disease or shorten its duration. Furthermore, data from several clinical trials, studies, and a national access program suggest that when given early in the disease or to those with weakened immune systems, convalescent plasma with high antibody levels may lessen the severity or shorten the duration of COVID-19 in some people.
Market Drivers
Rising prevalence of life-threatening disorders, especially hemophilia have gained significant attention for the global blood plasma derivatives market
Due to the rapid introduction of a number of new hemophilia treatment products, the hemophilia markets in high-income countries have seen more changes in the last 5 years than in the previous 30 years. The first notable change occurred in 2014 when Biogen (now Bioverativ) introduced the first extended half-life factors VIII and IX products. Shire, CSL Behring, and Novo Nordisk have all introduced extended half-life factor products since then, with several more in late-stage development. In addition, in November 2017, Roche received FDA approval for the first novel, non-factor therapy to treat hemophilia patients with inhibitors. This is the first monoclonal antibody to be used to treat hemophilia patients, as well as the first therapy to be administered subcutaneously. As IgG production has increased over the last few decades, so has the demand for more plasma. From approximately 16.4 million liters in 1990 to 33.6 million liters in 2010, the global supply of plasma for fractionation (source and recovered) reached an estimated 51.2 million liters in 2016. Two-thirds of this was made up of total plasma from the United States. In 2016, the United States supplied 74% of the world's source plasma. Because the FDA allows individuals to donate plasma more frequently and at a higher annual volume than any other country, this country is able to generate a higher volume of source plasma than other countries. While donor compensation is significant, it is not the primary reason for the United States' dominance in this field. The commercialization of new plasma-derived therapies is expected to skyrocket in the coming decade.
Increasing awareness about blood & plasma donation bolster the growth of global blood plasma derivatives market
According to a World Health Organization (WHO) report, 40% of the 118.5 million blood donations collected globally are collected in high-income countries that account for 16% of the world's population. In low-income countries, children under the age of five account for up to 54% of all blood transfusions, whereas in high-income countries, the most frequently transfused patient group is over 60 years old, accounting for up to 75% of all transfusions. Furthermore, to raise awareness of blood and plasma derivatives “WHA63.12” urges Member States to establish, implement, and support a nationally coordinated, efficiently managed, and sustainable blood and plasma program based on available resources, with the goal of achieving self-sufficiency. Individual governments are responsible for ensuring a sufficient and equitable supply of plasma-derived medicinal products, such as immunoglobulin’s and coagulation factors, which are required to prevent and treat a wide range of serious conditions that occur around the world. During the year, approximately 25.6 million liters of plasma from 39 reporting countries were fractionated for the production of PDMP. This includes approximately 47 % of the plasma recovered from whole blood donations.
Market Segmentation
The global blood plasma derivatives market is segmented based on type, application, and end-user. By type, the market is segmented as albumin, factor 8, factor 9, immunoglobulin, hyperimmune globulin, and others. Based on application, the market is segmented as hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's disease (VWD), and other applications. Further, end-user is segregated as hospitals, clinics, and other end-users.
Regional Framework
The global blood plasma derivatives market is expected to be dominated by North America. The market in North America is being driven by rising awareness about the use and availability of plasma derivatives for the treatment of infectious diseases. Asia Pacific, on the other hand, is expected to have the fastest growing CAGR during the analysis period. The high population base, increase in disposable income, and improvement in patient awareness of plasma derivatives are the major factors driving the global blood plasma derivatives market.
Competitive Landscape
The prominent players of the global blood plasma derivatives market involve Grifols, S.A., SK Plasma, Fusion Healthcare, Biotest AG, GC Pharma [Green Cross Corporation], Baxter International Inc., LFB S.A., Octapharma AG, CSL Limited, Shire plc, and among others
Market Segmentation
Market By Type
Albumin
Factor 8
Factor 9
Immunoglobulin
Hyper Immune Globulin
Others
Market By Application
Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willerbrands Disease (VWD)
Other Applications
Market By End-User
Hospitals
Clinics
Other End-Users
Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Blood Plasma Derivatives
1.1. Definition and Scope
1.1.1. Definition of Blood Plasma Derivatives
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Blood Plasma Derivatives Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Blood Plasma Derivatives Market By Type
1.2.3. Blood Plasma Derivatives Market By Application
1.2.4. Blood Plasma Derivatives Market By End-User
1.2.5. Blood Plasma Derivatives Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Blood Plasma Derivatives Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Blood Plasma Derivatives Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Price Trend of Key Raw Materials
3.8.2. Raw Material Suppliers
3.8.3. Proportion of Manufacturing Cost Structure
3.8.3.1. Raw Material
3.8.3.2. Labor Cost
3.8.3.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Application Source of Blood Plasma Derivatives Major Manufacturers in 2019
CHAPTER 5. Blood Plasma Derivatives Market By Type
5.1. Introduction
5.2. Blood Plasma Derivatives Revenue By Type
5.2.1. Blood Plasma Derivatives Revenue (US$ Mn) and Forecast, By Type, 2016-2027
5.2.2. Albumin
5.2.2.1. Albumin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Factor 8
5.2.3.1. Factor 8 Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Factor 9
5.2.4.1. Factor 9 Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.5. Immunoglobulin
5.2.5.1. Immunoglobulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.6. Hyper Immune Globulin
5.2.6.1. Hyper Immune Globulin Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.7. Other Applications
5.2.7.1. Other Applications Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Blood Plasma Derivatives Market Revenue By Application
6.1. Introduction
6.2. Blood Plasma Derivatives Revenue (US$ Mn) By Application
6.2.1. Blood Plasma Derivatives Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
6.2.2. Hemophilia
6.2.2.1. Hemophilia Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Hypogammaglobulinemia
6.2.3.1. Hypogammaglobulinemia Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Immunodeficiency Diseases
6.2.4.1. Immunodeficiency Diseases Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Von Willerbrands Disease (VWD)
6.2.5.1. Von Willerbrands Disease (VWD) Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Other Applications
6.2.6.1. Other Applications Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Blood Plasma Derivatives Market By End-User
7.1. Introduction
7.2. Blood Plasma Derivatives Revenue (US$ Mn) By End-User
7.2.1. Blood Plasma Derivatives Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
7.2.2. Hospitals
7.2.2.1. Hospitals Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Clinics
7.2.3.1. Clinics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Other End-Users
7.2.4.1. Other End-Users Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. North America Blood Plasma Derivatives Market By Country
8.1. North America Blood Plasma Derivatives Overview
8.2. U.S.
8.2.1. U.S. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.2.2. U.S. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.2.3. U.S. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
8.3. Canada
8.3.1. Canada Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
8.3.2. Canada Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
8.3.3. Canada Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
8.4. North America PEST Analysis
CHAPTER 9. Europe Blood Plasma Derivatives Market By Country
9.1. Europe Blood Plasma Derivatives Market Overview
9.2. U.K.
9.2.1. U.K. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.2.2. U.K. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.2.3. U.K. Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
9.3. Germany
9.3.1. Germany Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.3.2. Germany Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.3.3. Germany Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
9.4. France
9.4.1. France Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.4.2. France Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.4.3. France Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
9.5. Spain
9.5.1. Spain Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.5.2. Spain Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.5.3. Spain Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
9.6. Rest of Europe
9.6.1. Rest of Europe Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016-2027
9.6.2. Rest of Europe Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.6.3. Rest of Europe Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016-2027
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Blood Plasma Derivatives Market By Country
10.1. Asia Pacific Blood Plasma Derivatives Market Overview
10.2. China
10.2.1. China Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.2.2. China Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.2.3. China Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.3. Japan
10.3.1. Japan Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.3.2. Japan Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.3.3. Japan Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.4. India
10.4.1. India Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.4.2. India Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.4.3. India Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.5. Australia
10.5.1. Australia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.5.2. Australia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.5.3. Australia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.6. South Korea
10.6.1. South Korea Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.6.2. South Korea Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.6.3. South Korea Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
10.7.2. Rest of Asia-Pacific Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
10.7.3. Rest of Asia-Pacific Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Blood Plasma Derivatives Market By Country
11.1. Latin America Blood Plasma Derivatives Market Overview
11.2. Brazil
11.2.1. Brazil Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.2.2. Brazil Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.2.3. Brazil Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
11.3. Mexico
11.3.1. Mexico Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.3.2. Mexico Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.3.3. Mexico Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
11.4. Rest of Latin America
11.4.1. Rest of Latin America Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
11.4.2. Rest of Latin America Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 – 2027
11.4.3. Rest of Latin America Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 – 2027
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Blood Plasma Derivatives Market By Country
12.1. Middle East & Africa Blood Plasma Derivatives Market Overview
12.2. Saudi Arabia
12.2.1. Saudi Arabia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.2.2. Saudi Arabia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.2.3. Saudi Arabia Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
12.3. UAE
12.3.1. UAE Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.3.2. UAE Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.3.3. UAE Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 - 2027
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Type, 2016 - 2027
12.4.2. Rest of Middle East & Africa Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.4.3. Rest of Middle East & Africa Blood Plasma Derivatives Market Revenue (US$ Mn) and Forecast By End-User, 2016 – 2027
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Blood Plasma Derivatives
13.1. Blood Plasma Derivatives Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Blood Plasma Derivatives Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 14. COMPANY PROFILE
14.1. Grifols, S.A.
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (US$ Mn), 2019
14.1.3.2. Grifols, S.A. 2019 Blood Plasma Derivatives Business Regional Distribution
14.1.4. Product/ Service and Specification
14.1.5. Recent Developments & Business Strategy
14.1.6. Manufacturing Plant Footprint Analysis
14.2. SK Plasma
14.3. Fusion Healthcare
14.4. Biotest AG
14.5. GC Pharma [Green Cross Corporation]
14.6. Baxter International Inc.
14.7. LFB S.A.
14.8. Octapharma AG
14.9. CSL Limited
14.10. Shire plc
14.11. Others
